These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 23013350)

  • 1. A comparative study of neuroprotective effect of single and combined blockade of AT1 receptor and PARP-1 in focal cerebral ischaemia in rat.
    Singh N; Sharma G; Singh N; Hanif K
    Int J Stroke; 2014 Jul; 9(5):560-8. PubMed ID: 23013350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
    Engelhorn T; Doerfler A; Heusch G; Schulz R
    Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effect of combination of poly (ADP-ribose) polymerase inhibitor and antioxidant in middle cerebral artery occlusion induced focal ischemia in rats.
    Gupta S; Kaul CL; Sharma SS
    Neurol Res; 2004 Jan; 26(1):103-7. PubMed ID: 14977067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term neuroprotective effect of inhibiting poly(ADP-ribose) polymerase in rats with middle cerebral artery occlusion using a behavioral assessment.
    Ding Y; Zhou Y; Lai Q; Li J; Gordon V; Diaz FG
    Brain Res; 2001 Oct; 915(2):210-7. PubMed ID: 11595210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.
    Brdon J; Kaiser S; Hagemann F; Zhao Y; Culman J; Gohlke P
    J Hypertens; 2007 Jan; 25(1):187-96. PubMed ID: 17143191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase.
    Moroni F; Cozzi A; Chiarugi A; Formentini L; Camaioni E; Pellegrini-Giampietro DE; Chen Y; Liang S; Zaleska MM; Gonzales C; Wood A; Pellicciari R
    Br J Pharmacol; 2012 Mar; 165(5):1487-500. PubMed ID: 21913897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats.
    Groth W; Blume A; Gohlke P; Unger T; Culman J
    J Hypertens; 2003 Nov; 21(11):2175-82. PubMed ID: 14597862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.
    Fu H; Hosomi N; Pelisch N; Nakano D; Liu G; Ueno M; Miki T; Masugata H; Sueda Y; Itano T; Matsumoto M; Nishiyama A; Kohno M
    J Hypertens; 2011 Nov; 29(11):2210-9. PubMed ID: 21934531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effect of peroxynitrite decomposition catalyst and poly(adenosine diphosphate-ribose) polymerase inhibitor alone and in combination in rats with focal cerebral ischemia.
    Sharma SS; Munusamy S; Thiyagarajan M; Kaul CL
    J Neurosurg; 2004 Oct; 101(4):669-75. PubMed ID: 15481724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
    Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats.
    Nakajima H; Kakui N; Ohkuma K; Ishikawa M; Hasegawa T
    J Pharmacol Exp Ther; 2005 Feb; 312(2):472-81. PubMed ID: 15466246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
    Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
    J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model.
    Ikeda Y; Hokamura K; Kawai T; Ishiyama J; Ishikawa K; Anraku T; Uno T; Umemura K
    Brain Res; 2005 Oct; 1060(1-2):73-80. PubMed ID: 16202986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropilin-1 modulates vascular endothelial growth factor-induced poly(ADP-ribose)-polymerase leading to reduced cerebrovascular apoptosis.
    Mey L; Hörmann M; Schleicher N; Reuter P; Dönges S; Kinscherf R; Gassmann M; Gerriets T; Al-Fakhri N
    Neurobiol Dis; 2013 Nov; 59():111-25. PubMed ID: 23816753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat.
    Lou M; Blume A; Zhao Y; Gohlke P; Deuschl G; Herdegen T; Culman J
    J Cereb Blood Flow Metab; 2004 May; 24(5):536-47. PubMed ID: 15129186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperative effect of angiotensin AT(1) and endothelin ET(A) receptor antagonism limits the brain damage after ischemic stroke in rat.
    Stenman E; Jamali R; Henriksson M; Maddahi A; Edvinsson L
    Eur J Pharmacol; 2007 Sep; 570(1-3):142-8. PubMed ID: 17597600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
    Culman J; Jacob T; Schuster SO; Brolund-Spaether K; Brolund L; Cascorbi I; Zhao Y; Gohlke P
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Sep; 390(9):949-959. PubMed ID: 28669009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress.
    Hamai M; Iwai M; Ide A; Tomochika H; Tomono Y; Mogi M; Horiuchi M
    Neuropharmacology; 2006 Sep; 51(4):822-8. PubMed ID: 16824557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.
    Omura-Matsuoka E; Yagita Y; Sasaki T; Terasaki Y; Oyama N; Sugiyama Y; Okazaki S; Sakoda S; Kitagawa K
    Hypertens Res; 2009 Jul; 32(7):548-53. PubMed ID: 19424281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats.
    Engelhorn T; Goerike S; Doerfler A; Okorn C; Forsting M; Heusch G; Schulz R
    J Cereb Blood Flow Metab; 2004 Apr; 24(4):467-74. PubMed ID: 15087716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.